PA8.F stock up 38% intraday on XETRA 20 Mar 2026: assess catalysts and liquidity

PA8.F stock jumped 38.33% intraday to €0.10 on XETRA on 20 Mar 2026, making it one of Germany’s top gainers today. The move came on light volume of 325 shares versus an average of 2,162, suggesting a short, sharp re-rating rather than broad buying. We see the spike tied to limited float, a low 50-day average price of €0.02, and company-level developments noted in market reports. As an AI-powered market analysis platform, Meyka AI tracks these bursts and links them to liquidity, sector context and upcoming catalysts.

PA8.F stock intraday move and drivers

Paion AG (PA8.F) traded on XETRA in Germany recorded a €0.10 last price after opening at €0.04 on 20 Mar 2026. The 38.33% one-day gain follows thin liquidity and news coverage of company sites across Germany, the UK and the US source. Low float and a tight bid-ask can produce outsized intraday moves in small-cap healthcare names.

PA8.F stock valuation and key metrics

PA8.F shows a market cap of €710,517 and 7,133,700 shares outstanding, giving severe micro-cap dynamics. Valuation ratios point to deep discounting: Price/Sales 0.02 and EV/EBITDA 0.16. Net income per share is -0.08, and P/E is not meaningful due to negative earnings. These figures reflect early-stage commercial scale and financial fragility.

PA8.F stock technicals and volume

Technical indicators show momentum but remain mixed: RSI 56.16 and ADX 21.97 suggest a modest trend. Day range was €0.04–€0.10, and Bollinger Bands run 0.04–0.11, highlighting volatility. Trading volume today of 325 shares is below the 2,162 average, supporting the view this was a concentrated move rather than broad market participation.

Meyka AI rates PA8.F with a score out of 100

Meyka AI rates PA8.F with a score out of 100: the model assigns a 62.55 score, grade B and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not investment advice.

PA8.F stock forecast and price targets

Meyka AI’s forecast model projects a short-term monthly figure of €0.07 versus the current price €0.0996. That projection implies a model-based downside of -29.72% from the quoted price. Analysts should weigh this model output with the stock’s extreme volatility and lack of broad coverage.

PA8.F stock risks and outlook

Key risks include low liquidity, negative net income, and thin analyst coverage in the Healthcare sector where peers trade at far higher volumes and multiples. Offsetting opportunities include innovation in short-acting sedatives and licensing deals. Upcoming earnings on 02 Apr 2026 could act as a fresh catalyst or trigger renewed volatility.

Final Thoughts

PA8.F stock is a high-volatility micro-cap that led XETRA top gainers on 20 Mar 2026 with a 38.33% intraday jump to €0.0996. The move reflects thin liquidity and short-term re-rating rather than a confirmed fundamental turn. Valuation metrics show Price/Sales 0.02 and EV/EBITDA 0.16, but earnings remain negative at -€0.08 per share. Meyka AI’s forecast model projects €0.07, implying -29.72% from the current quote €0.0996; forecasts are model-based projections and not guarantees. Given the grade B (62.55) and a HOLD suggestion, a disciplined approach is warranted: consider position sizing limits, watch volume and the earnings date 02 Apr 2026, and use stop limits to manage execution risk. For investors focused on healthcare exposure, PA8.F offers speculative upside tied to specific product or licensing news, but it remains a trading, not a core, portfolio holding.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.